Showing 6481-6490 of 7665 results for "".
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- Mayne Pharma Acquires FDA-approved Halobetasol Foamhttps://practicaldermatology.com/news/mayne-pharma-acquires-fda-approved-halobetasol-foam/2457520/Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for an investment of up to $32 million (comprising $10 million in cash up front, $5 million at commercial launch plus continge
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month/2457519/November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society (IHhS) wants the world to know that hyperhidrosis’ (Hh) uncontrollable, no-fault sweating can soak through clothing and water-damage electronics. This makes
- Endocannabinoids Effective in Lupus Modelhttps://practicaldermatology.com/news/endocannabinoids-effective-in-lupus-model/2457521/Zylö Therapeutics’ patented Nanopod™ aerogel delivery technology was used to demonstrate the efficacy of endocannabinoids in a model of cutaneous lupus in a study presented last month at the meeting of the American College of Rheumatology. There is growing evidence that t
- AAD Releases New Melanoma Guidelineshttps://practicaldermatology.com/news/aad-releases-new-melanoma-guidelines/2457522/As National Healthy Skin Month begins, the American Academy of Dermatology’s (AAD) new melanoma guidelines shed light on risk of melanoma prognosis during pregnancy, the role of formal genetic testing in at-risk families and other aspects of care for primary cutaneous melanoma.
- New AD Estimate: As Many As 16.5 Million Adults Have ADhttps://practicaldermatology.com/news/new-ad-estimate-as-many-as-165-million-adults-have-ad/2457524/As many as 16.5 million adults in America have atopic dermatitis (AD). This estimate comes from a new study from the Perelman School of Medicine at the University of Pennsylvania, which also projected 6.6 million of these adults have disease that wo
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- IBD Linked to Psoriasis in Large Meta-Analysishttps://practicaldermatology.com/news/ibd-linked-to-psoriasis-in-large-meta-analysis/2457531/A new meta-analysis comprising more than 7 million people suggests it may be time to add inflammatory bowel disease (IBD) to the list of comorbidities associated with psoriasis. The findings appear in
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s
- Scott Peterson, PhD to Head Medical Affairs at Evolushttps://practicaldermatology.com/news/scott-peterson-phd-to-head-medical-affairs-at-evolus/2457535/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti